Loading…
Company advances development of AD04 with FDA support.
Adial Pharmaceuticals, Inc. (ADIL) announced on February 25, 2025, that it received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its proposed in vitro bridging strategy for AD04.
The FDA's positive feedback supports Adial's approach to demonstrate the comparability of AD04 manufactured at different scales and sites, which is a critical step in the drug's development process.
As of the latest available data, Adial Pharmaceuticals has a free float of 23,878,900 shares and 26,649,600 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.